Abstract:Abstract Introduction : Reactive oxygen species (ROS) are produced by every aerobic cell during mitochondrial oxidative metabolism as well as in cellular response to xenobiotics, cytokines, and bacterial invasion. Oxidative stress is due to an imbalance between ROS or oxidants generation over the capability of the cell to elaborate an effective antioxidant response. Superoxide Dismutases (SOD) are antioxidant proteins that convert superoxide anion (O2•-) to hydrogen peroxide (H2O2). SOD mimetics can enhance the production of H2O2 and improve cytotoxic effect of chemotherapy. By using the differential in level of oxidative stress between normal and cancer cells, SOD mimetics can show an anti-tumoral effect and prevent oxaliplatin induced neuropathy. A new Pt(IV) conjugate prodrug called MAGOX, combining oxaliplatin and a Mn SOD mimic (MnSODm Mn1C1A) with a covalent link, was created. Methods In vitro, MAGOX anti-tumoral activity was assessed by the viability and ROS production of tumor cell lines (CT16, HCT 116, KC) and fibroblasts (primary culture and NIH 3T3) treated with Mn1C1A alone, conjugates (MAG2OX, MAGOX mono-OH, MAGOX mono-OAc), oxaliplatin and vehicle. In vivo, a murine model of colorectal cancer was created with subcutaneous injection of CT26 cells. After tumor growth, Balb/c mice underwent randomization in 4 groups: vehicle, oxaliplatin, MAG2OX and Mn1C1A. Tumor size and volume were measured weekly. Oxaliplatin induced peripheral neuropathy was assessed using a Von Frey test reflecting chronic hypoalgesia. Tolerance to treatment was assessed with a clinical score including 4 items: weight loss, weariness, alopecia and diarrhea. Results : In vitro, the MnSODm associated with oxaliplatin and MAG2OX treatment induced a significant higher production of H2O2 in all cell lines, by itself. In the group of cell lines treated with the association of Mn1C1A and oxaliplatin and the group treated with MAG2OX, a significant improvement of the anti-tumoral efficacy compared to oxaliplatin alone was observed. In vivo, the association of Mn1C1A to oxaliplatin did not decrease its anti-tumoral activity and MAG2OX had a lower anti-tumoral activity than oxaliplatin alone. Mn1C1A associated with oxaliplatin significantly decreased oxaliplatin induced peripheral neuropathy and also improved global clinical tolerance of oxaliplatin, therefore mice treated with Mn1C1A + oxaliplatin could receive more cumulated dose of oxaliplatin. Seric advanced oxidative protein products were higher in the Mn1C1A + oxaliplatin group versus oxaliplatin alone. PCR VEGF showed a higher VEGF RNA production in tumoral cells of mice treated with Mn1C1A than the other groups, as well as higher production of LC3 reflecting autophagy. Conclusion : A new Mn SOD mimetic called Mn1C1A associated with oxaliplatin showed superior anti tumoral activity than oxaliplatin, in vitro. The first Pt(IV) conjugate MAGOX had lower antitumoral activity, probably due to chemical instability issues. A new design is being evaluated. In vivo we observed a neuroprotective effect associated with a tolerance to oxaliplatin significantly improved, without impairing its antitumoral activity.

Optimizing Oxygen-Production Kinetics of Manganese Dioxide Nanoparticles Improves Hypoxia Reversal and Survival in Mice with Bone Metastases

Reversing Hypoxia With Plga-Encapsulated Manganese Dioxide Nanoparticles Improves Natural Killer Cell Response To Tumor Spheroids

Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages Toward M1-Like Phenotype and Attenuating Tumor Hypoxia

Nanoparticle Delivery of MnO 2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma

An Oxygen‐Self‐Produced Nanoplatform Based on MnO2 for Relieving Hypoxia

Overcoming chemotherapy resistance using pH-sensitive hollow MnO2 nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma

Facile Deposition of Manganese Dioxide to Albumin-Bound Paclitaxel Nanoparticles for Modulation of Hypoxic Tumor Microenvironment to Improve Chemoradiation Therapy.

Ultra-dispersed biomimetic nanoplatform fabricated by controlled etching agglomerated MnO2 for enhanced photodynamic therapy and immune activation

A new Manganese superoxide dismutase mimetic improves oxaliplatin induced neuropathy and global tolerance on mice.

Modulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors

Graphdiyne-templated palladium-nanoparticle assembly as a robust oxygen generator to attenuate tumor hypoxia

Oxygen‐Evolving Manganese Ferrite Nanovesicles for Hypoxia‐Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy

Manganese porphyrin-based metal-organic framework for synergistic sonodynamic therapy and ferroptosis in hypoxic tumors

Outer Membrane Vesicle-Wrapped Manganese Nanoreactor for Augmenting Cancer Metalloimmunotherapy through Hypoxia Attenuation and Immune Stimulation

In situ synthesis of MnO 2 micro/nano-adjuvants for enhanced immunotherapy of breast tumors

Hypoxia-Responsive Stereocomplex Polymeric Micelles with Improved Drug Loading Inhibit Breast Cancer Metastasis in an Orthotopic Murine Model.

Manganese-Enriched Zinc Peroxide Functional Nanoparticles for Potentiating Cancer Immunotherapy

Manganese Dioxide‐Based Nanocarrier Delivers Paclitaxel to Enhance Chemotherapy against Orthotopic Glioma through Hypoxia Relief

Nanoparticle‐Stabilized Oxygen Microcapsules Prepared by Interfacial Polymerization for Enhanced Oxygen Delivery

Investigation of PPIX-Lipo-MnO2 to Enhance Photodynamic Therapy by Improving Tumor Hypoxia.

Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO2 nanosheets prompt pro-inflammatory macrophage polarization